Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

-0.03 (-1.19%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
4,871 shs
Average Volume
14,713 shs
Market Capitalization
$90.38 million
P/E Ratio
Dividend Yield
Price Target

Armata Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
180.0% Upside
$7.00 Price Target
Short Interest
0.13% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($1.34) to ($1.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.68 out of 5 stars

ARMP stock logo

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

ARMP Stock Price History

ARMP Stock News Headlines

Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
INVA Apr 2024 15.000 call
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
INVA Mar 2024 7.500 call
Armata Pharmaceuticals Inc (ARMP)
Armata Pharmaceuticals Inc ARMP
Lexeo Therapeutics Inc.
See More Headlines
Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$4.53 million
Book Value
($0.89) per share


Free Float
Market Cap
$90.38 million
Not Optionable
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Mina Pastagia M.D. (Age 49)
    MS, Chief Medical Officer
    Comp: $537.6k
  • Dr. Deborah L. Birx M.D. (Age 67)
    CEO & Director
  • Mr. Richard Rychlik (Age 68)
    VP, Corporate Controller & Principal Financial Officer

ARMP Stock Analysis - Frequently Asked Questions

Should I buy or sell Armata Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARMP shares.
View ARMP analyst ratings
or view top-rated stocks.

What is Armata Pharmaceuticals' stock price target for 2024?

1 brokers have issued 12-month price targets for Armata Pharmaceuticals' stock. Their ARMP share price targets range from $7.00 to $7.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 180.0% from the stock's current price.
View analysts price targets for ARMP
or view top-rated stocks among Wall Street analysts.

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 14,200 shares, an increase of 6.8% from the March 15th total of 13,300 shares. Based on an average daily volume of 18,300 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.1% of the company's shares are sold short.
View Armata Pharmaceuticals' Short Interest

When is Armata Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ARMP earnings forecast

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings data on Thursday, March, 21st. The company reported ($0.55) EPS for the quarter. The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.68 million. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 280.95% and a negative net margin of 1,524.51%.

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD).

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include SeaCrest Wealth Management LLC (0.09%).
View institutional ownership trends

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ARMP) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners